WO1997013508A1 - Topical liquid composition, method for preparing same and uses thereof - Google Patents
Topical liquid composition, method for preparing same and uses thereof Download PDFInfo
- Publication number
- WO1997013508A1 WO1997013508A1 PCT/FR1996/001589 FR9601589W WO9713508A1 WO 1997013508 A1 WO1997013508 A1 WO 1997013508A1 FR 9601589 W FR9601589 W FR 9601589W WO 9713508 A1 WO9713508 A1 WO 9713508A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- solvent
- closantel
- composition according
- sodium salt
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
Definitions
- the present invention relates to a liquid endoparasiticidal composition for topical use, active on helminthiasis caused by the fluke (Fasciola hepatica or Fasciola magna), in warm-blooded animals, excluding humans; such a composition comprises sodium salt of closantel as the main anthelmintic active principle, optionally combined with another anthelmintic agent, in solution in a solvent or a mixture of non-aqueous solvents, chosen for their property of passage through the barrier cutaneous.
- a composition is particularly well suited to obtaining an effective systemic amount of closantel. Different clinical symptoms are associated with a fluke infection; they depend in particular on the stage of advancement of the infestation and the number of sites.
- Acute fluke infestation appears when the metacercariae invades the liver; in the most serious cases, the damage produced in the hepatic tissues and the inflammatory reactions are such that a fatal outcome is foreseeable.
- Chronic conditions develop slowly, causing cholangitis, biliary obstruction, destruction of liver tissue, fibrosis and anemia. This infection obviously limits the growth of the animal and its food assimilation capacity, thereby reducing the production of meat in cattle and the production of milk in dairy cows.
- Closantel or (N- [5-chloro-4- [(4-chlorophenyl) cyano methyl] -2-methylphenyl] -2-hydroxy-3, 5-diodo benzamide) has been used for many years for the treatment of fasciololic or animal douvicide, injectable or orally.
- the closantel's douvicide activity against Fasciola hepatica has been widely confirmed in the field (Maes L. Rev. Médet Vet. Toulouse, 1990, 14, 12, 991-995 and comparisons of activity between various anthelmintics demonstrate good efficacy 5 mg / kg and 10 mg / kg orally (Guerrero J. Préventive Veterinary Medicine, 2 (1984) 317-327).
- Rothwell JT in Int. J. Parasi tol, 1993, 23, 5, 573 -578 and 23, 7, 885-889, demonstrates a comparable efficacy in goats and sheep, while Hennessy DR in J. Vet. Pharmacol. Ther., 1993, 16, 3, 254-260 notes a different pharmacokinetic profile, depending on the species, during treatment by injection, in particular at the dose of 7.5 mg / kg.
- this difference between species can call into question the choice of routes of administration.
- the dispersal of cattle in extensive farms makes the mode of topical administration preferable to other modes of administration.
- this route of administration is also preferred by its ease of use both in relation to administration by the oral route and by the parenteral route.
- the breeder administering a topical treatment appreciates the time saved, the absence of irritation, pain or nervousness in the animal as well as the resulting gain in labor. .
- compositions for topical use must be dissolved or dispersed in a solvent suitable for the active principle, favorable for passage through the skin barrier (percutaneous or transdermal route ⁇ and well tolerated by the animal.
- the active principle thus formulated must be well assimilated after its passage through the skin of the animal .
- the Applicant has found, unexpectedly, that the sodium salt of closantel is absorbed through the skin of the animal, when it is in solution in a non-aqueous solvent, suitable for being poured in greater or lesser quantities onto the animal.
- the Applicant has thus obtained excellent results in the control of the liver fluke in warm-blooded animals, by administering the sodium derivative of closantel in a non-aqueous composition.
- the subject of the present invention is a liquid composition for topical use, comprising at least one anthelmintic in a nonaqueous solvent as active substance, which composition is characterized in that it consists essentially of sodium salt of closantel. dissolved in at least one non-aqueous solvent, chosen from the group consisting of polyalcohols, their ethers and mixtures thereof, which cross the skin barrier and which promote the transdermal passage of said closantel.
- composition further comprises at least one co-solvent, capable of stimulating the passage of closantel towards the deep layers of the skin, which co-solvent is selected from the group consisting of fatty alcohols, amides, fatty acid esters, functional monocyclic derivatives, essential oils, tallow oxides and nonionic surfactants, for obtaining an effective systemic endoparasiticide (douvicide) amount of closan ⁇ tel.
- co-solvent is selected from the group consisting of fatty alcohols, amides, fatty acid esters, functional monocyclic derivatives, essential oils, tallow oxides and nonionic surfactants, for obtaining an effective systemic endoparasiticide (douvicide) amount of closan ⁇ tel.
- the polyalcohols and their ethers are selected from the group consisting of glycerol; sorbitol; glycols, such as: propylene glycol, diethylene glycol, butyl diglycol, polyethylene glycol or their mono- or poly-ethers such as methoxyethanol, butoxyethoxyethanol, propylene glycol or ethylene glycol monobutyl ether, dipropylene glycol monomethyl ether, monomethyl ether, monobutyl ether or tripropylene glycol monopropyl ether, dimethyl isosorbide.
- glycols such as: propylene glycol, diethylene glycol, butyl diglycol, polyethylene glycol or their mono- or poly-ethers such as methoxyethanol, butoxyethoxyethanol, propylene glycol or ethylene glycol monobutyl ether, dipropylene glycol monomethyl ether, monomethyl ether, monobutyl ether or tripropylene glycol monopropyl ether, dimethyl isosorb
- N- [5-chloro-4- [(4-chlorophenyl) cyanomethyl] -2-methylphenyl] -2-hydroxy-3, 5-diodo benzamide has been used as a douvicide in animals, especially in bovine, parenterally at a dose of 2.5 mg to 5 mg / kg of animal weight
- the Applicant has found that, unexpectedly, the sodium salt of closantel, which is very slightly soluble in water, but which offers a fairly good solubility in solvents of the hydroxyether or poly ⁇ alcohol type such as diethylene glycol or monobutylethylene glycol, passes actively through the epidermis and the deep layers, when it is in solution in said solvents, thus resulting in a plasma level equivalent to that obtained during IM, SC or oral administration.
- the co-solvent capable of enhancing the passage of the active ingredient (s) towards the deep layers of the skin is in particular selected from fatty alcohols, more particularly n-dodecanol, amides , such as the di- methylacetamide (DMAC), n-butyl-n-dodecylamide, di ⁇ methylformamide (DMF), fatty acid esters chosen, preferably from isopropylmyristate, methyl laurate, glycerol monolaurate or propylene glycol , functional monocyclic derivatives such as cycloalkanone, N-methylpyrrolidone, l-alkylazacycloheptane-2-one, essential oils or derivatives including menthol, 1-carvone, eucalyptol, eugenol, sulfur derivatives, such as dimethylsulfoxide (DMSO), decylmethylsulfoxide, surfactants, and more specifically nonionic surfact
- fatty alcohols more particularly
- Said co-solvent is advantageously present in a proportion generally less than 20%, more generally between 0.5 and 10%.
- said co-solvent is preferably selected from the group consisting of dimethylsulfoxide (DMSO), dimethylformamide (DMF), dimethylacetamide (DMAC) and N-methylpyrrolidone.
- composition it can also advantageously comprise additives such as film-forming agents such as acrylic polymers or copolymers; dyes which allow the application to be traced on the animal, in particular chosen from non-toxic products such as patent blue, Rhodamine or even Gentian violet, at concentrations of a few milligrams per liter; of the stabilizing agents, such as phenolic derivatives at concentrations less than or equal to 1%, preferably between 0.05 and 0.1%.
- film-forming agents such as acrylic polymers or copolymers
- dyes which allow the application to be traced on the animal in particular chosen from non-toxic products such as patent blue, Rhodamine or even Gentian violet, at concentrations of a few milligrams per liter
- stabilizing agents such as phenolic derivatives at concentrations less than or equal to 1%, preferably between 0.05 and 0.1%.
- a second anthelmintic present in proportions of between 0.01% and 10% (w / v), preferably between 0.01 and 2%.
- said composition essentially comprises between 10 and 40% of sodium salt of closantel, between 0.1 and 1% of an avermectin, between 49 and
- solvent such as propylene glycol and 1 to 10% of co-solvent, such as dimethylformamide.
- the present invention also relates to a process for preparing the composition according to the invention, characterized in that it comprises the following steps:
- the present invention also relates to the use of a liquid composition for topical use according to the invention, for obtaining a medicament with systemic activity, intended for the treatment of helminthiasis.
- said topical administration is carried out by application to a more or less large area of the animal, at a rate of 10 to 40 mg / kg.
- the composition is applied topically to the animal by pouring it onto the back of the animal, along the spine for example or applied over a less extensive area for more concentrated preparations.
- Means such as brushes or applicator rollers can be used as well as pouring dosing containers or dosing syringes equipped with an appropriate nozzle.
- FIG. 1 shows the average plasma concentration of closantel in mg / ml, depending on the route of administration.
- closantel sodium salt are dispersed with vigorous stirring, in a mixture comprising 10 ml of DMSO (co-solvent) and 60 ml of propylene glycol monobutyl ether (solvent) and the mixture is brought to 80 ° C. for 5 minutes , then at 50 ° C for 30 minutes.
- DMSO co-solvent
- propylene glycol monobutyl ether solvent
- Example 5 The procedure is carried out under the conditions of the preceding example, using 30 g of closantel sodium salt, 10 ml of dimethylacetamide (co-solvent), 5 ml of N-methylpyrroli ⁇ done (co-solvent) and 65 ml of ethylene glycol (solvent). After complete dissolution, 1 g of semi-synthetic polysaccharide (Klucel-HF-Aqualon ® ) and 0.5 ml of Tween 80 are added, followed by optional addition to 100 ml.
- Klucel-HF-Aqualon ® semi-synthetic polysaccharide
- Tween 80 0.5 ml of Tween 80
- composition according to Example 1 is applied to the back of cattle at the rate of 10 mg, 20 mg, 30 and 40 mg / kg of bodyweight.
- Four groups of six cattle weighing approximately 300 kg were thus formed.
- a fifth group is treated subcutaneously at 2.5 mg / kg, while a sixth group is treated orally at 10 mg / kg and serve as positive controls.
- Blood samples are taken from all the animals on the following days: D0, Dl, D3, D7, D10, D12, D14, D16, D18, D21, D28.
- the samples are centrifuged and the plasma concentration of closantel is determined by known HPLC methods. The results are collated in Table I.
- a topical administration of a composition according to the invention at 20 mg / kg provides a plasma concentration in closantel comparable to that obtained with a subcutaneous injectable formulation at 2 , 5 mg / kg.
- a topical formulation at 40 mg / kg has an efficacy comparable to an administration of 10 mg / kg orally. (See figure 1). Table I
- EXAMPLE 7 An experimental infestation is carried out with fluke larvae (at least 200) at the metacercaria stage, on cattle weighing 300 kg. After a period of 14 weeks, corresponding to the stage of development and migration of the immature forms to their final target organ, the liver, the liquid formulation according to Example 1 is administered, at a rate of 30 mg / kg live cattle. This is achieved by pouring 30 ml of liquid formulation on the back of the animal, along the spine. After two weeks, the animals are slaughtered, the liver is removed, then the parasites are counted. On 6 treated animals, the efficiency is 97.4%.
- Table II illustrates the results obtained and shows the systemic efficacy of closantel sodium salt, administered locally, at 1 ml / 10 kg (30 mg / kg), in the form of a liquid solution as defined above. , on an endoparasite, Fasciola hepa tica.
- the concentration of closantel sodium salt to be used in this formulation must be between 1 and 60% and more particularly between 5 and 40%.
- the concentration thereof must be between 0.01% and 10%, preferably between 0.1 and 2%.
- This second antiparasitic active principle is chosen from the family of avermectins comprising inter alia abamectin and ivermectin.
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP96934896A EP0859609A1 (en) | 1995-10-13 | 1996-10-11 | Topical liquid composition, method for preparing same and uses thereof |
AU73041/96A AU7304196A (en) | 1995-10-13 | 1996-10-11 | Topical liquid composition, method for preparing same and uses thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9512458A FR2739778B1 (en) | 1995-10-13 | 1995-10-13 | TOPICAL FORMULATION FOR TREATING LIVER DISEASE DISEASE IN ANIMALS |
FR95/12458 | 1995-10-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997013508A1 true WO1997013508A1 (en) | 1997-04-17 |
Family
ID=9483817
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1996/001589 WO1997013508A1 (en) | 1995-10-13 | 1996-10-11 | Topical liquid composition, method for preparing same and uses thereof |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0859609A1 (en) |
AU (1) | AU7304196A (en) |
FR (1) | FR2739778B1 (en) |
WO (1) | WO1997013508A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2403905A (en) * | 2003-07-12 | 2005-01-19 | Norbrook Lab Ltd | Parasiticidal composition |
EP2065042A2 (en) | 2004-02-02 | 2009-06-03 | Wyeth | Antiparasitic composition containing an organic amine salt of closantel |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2386066A (en) * | 2002-02-28 | 2003-09-10 | Norbrook Lab Ltd | Long-acting parasiticidal composition with improved bioavailability comprising a salicylanilide, a further anti-parasitic compound & a polymeric species |
FR2839614B1 (en) * | 2002-05-14 | 2004-08-13 | Virbac Sa | NEW OIL PEST ORAL OIL COMPOSITIONS |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0059074A1 (en) * | 1981-02-23 | 1982-09-01 | Sankyo Company Limited | Anthelmintic composition and the use thereof |
EP0120286A1 (en) * | 1983-02-22 | 1984-10-03 | The Wellcome Foundation Limited | Pesticidal pour-on oil formulations |
EP0427582A2 (en) * | 1989-10-12 | 1991-05-15 | Michael John Crooks | Non-aqueous micellar solutions of various drugs |
WO1995005812A1 (en) * | 1993-08-24 | 1995-03-02 | Ashmont Holdings Limited | Anthelmintic formulations |
-
1995
- 1995-10-13 FR FR9512458A patent/FR2739778B1/en not_active Expired - Fee Related
-
1996
- 1996-10-11 EP EP96934896A patent/EP0859609A1/en not_active Withdrawn
- 1996-10-11 WO PCT/FR1996/001589 patent/WO1997013508A1/en not_active Application Discontinuation
- 1996-10-11 AU AU73041/96A patent/AU7304196A/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0059074A1 (en) * | 1981-02-23 | 1982-09-01 | Sankyo Company Limited | Anthelmintic composition and the use thereof |
EP0120286A1 (en) * | 1983-02-22 | 1984-10-03 | The Wellcome Foundation Limited | Pesticidal pour-on oil formulations |
EP0427582A2 (en) * | 1989-10-12 | 1991-05-15 | Michael John Crooks | Non-aqueous micellar solutions of various drugs |
WO1995005812A1 (en) * | 1993-08-24 | 1995-03-02 | Ashmont Holdings Limited | Anthelmintic formulations |
Non-Patent Citations (1)
Title |
---|
DATABASE CHEMABS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; D. R. HENNESSY ET AL: "Comparative pharmacokinetic disposition of closantel in sheep and goats", XP002006428 * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004257450B2 (en) * | 2003-07-12 | 2008-08-28 | Norbrook Laboratories Limited | Parasiticidal composition |
GB2403905A (en) * | 2003-07-12 | 2005-01-19 | Norbrook Lab Ltd | Parasiticidal composition |
GB2403905B (en) * | 2003-07-12 | 2005-12-14 | Norbrook Lab Ltd | Parasiticidal composition |
US20060142216A1 (en) * | 2003-07-12 | 2006-06-29 | William Blakely | Parasiticidal composition |
JP2007528866A (en) * | 2003-07-12 | 2007-10-18 | ノルブルック ラボラトリーズ リミテッド | Anthelmintic composition |
EA009602B1 (en) * | 2003-07-12 | 2008-02-28 | Норбрук Лэборетериз Лимитед | Antiparasiticidal composition |
WO2005007241A1 (en) * | 2003-07-12 | 2005-01-27 | Norbrook Laboratories Limited | Parasiticidal composition |
US8993546B2 (en) | 2003-07-12 | 2015-03-31 | Norbrook Laboratories Limited | Parasiticidal composition |
JP4677405B2 (en) * | 2003-07-12 | 2011-04-27 | ノルブルック ラボラトリーズ リミテッド | Anthelmintic composition |
EP2286876A1 (en) | 2003-07-12 | 2011-02-23 | Norbrook Laboratories Limited | Parasiticidal composition |
AP2956A (en) * | 2003-07-12 | 2014-08-31 | Norbrook Lab Ltd | Parasiticidal composition |
CN1822880B (en) * | 2003-07-12 | 2012-07-11 | 诺布鲁克有限公司 | Parasiticidal composition |
US7666444B2 (en) | 2004-02-02 | 2010-02-23 | Wyeth | Antiparasitic composition |
EP2065042A2 (en) | 2004-02-02 | 2009-06-03 | Wyeth | Antiparasitic composition containing an organic amine salt of closantel |
Also Published As
Publication number | Publication date |
---|---|
EP0859609A1 (en) | 1998-08-26 |
FR2739778A1 (en) | 1997-04-18 |
FR2739778B1 (en) | 1997-12-12 |
AU7304196A (en) | 1997-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1265617B1 (en) | Novel topical oestroprogestational compositions with systemic effect | |
FR2753377A1 (en) | NOVEL PARASITICIDE ASSOCIATION BASED ON 1-N-PHENYLPYRAZOLES AND ENDECTOCIDAL MACROCYCLIC LACTONES | |
JP4817515B2 (en) | Sustained release composition for parenteral administration | |
WO2013182990A1 (en) | Oxyclozanide-based veterinary composition for administration to the skin | |
CA2364742C (en) | Anthelmintic composition | |
BE1010974A3 (en) | Methods of disposal of parasites, and including ectoparasites vertebrate including mammals and compositions for the implementation of this method. | |
TW200906382A (en) | Stable non-aqueous pour-on compositions | |
LU86068A1 (en) | PERCUTANEOUS ANESTHETIC COMPOSITION FOR TOPICAL USE AND METHOD OF APPLICATION | |
LU82360A1 (en) | INJECTABLE OXYTETRACYCLINE COMPOSITIONS | |
FR2504779A1 (en) | INSECTICIDE COMPOSITION BASED ON CYPERMETHRIN | |
WO1997013508A1 (en) | Topical liquid composition, method for preparing same and uses thereof | |
KR870001791B1 (en) | Non-irritating tetramisole or levamisole pour-on composition | |
FR2517207A1 (en) | TOPICAL PARASITICIDE COMPOSITIONS BASED ON LEVAMISOLE AND CYHALOTHRIN | |
FR2609631A1 (en) | Stable liquid compositions based on biothionol | |
EP0209462A1 (en) | Liquid stable anthelmintic and fungicidal composition based on bithionol sulfoxide | |
AU2001235489B2 (en) | Veterinary compositions for the treatment of parasitic diseases | |
EP1940396B1 (en) | Anthelmintic formulations | |
FR2755824A1 (en) | New composition(s) for treating parasitic infection(s) in animals | |
AU2001235489A1 (en) | Veterinary compositions for the treatment of parasitic diseases | |
WO2009083520A2 (en) | Liquid oral florfenicol compositions which can be diluted in drinking water | |
EP1503733B1 (en) | Oleaginous oral antiparasitic compositions | |
FR2609714A1 (en) | Stable liquid compositions based on fungicidal imidazole derivatives | |
AU2004101084A4 (en) | Anthelmintic compositions | |
AU2004101082A4 (en) | Anthelmintic compositions | |
AU2005201107B8 (en) | Anthelmintic compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AU BA BB BG BR CA CN CU CZ EE GE HU IL IS JP KG KP KR LC LK LR LT LV MD MG MK MN MX NO NZ PL RO SG SI SK TR TT UA US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1996934896 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1996934896 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 97514778 Format of ref document f/p: F |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996934896 Country of ref document: EP |